<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 9/23/2021 8:25:16 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: a0c0c462-2e02-4bc0-8b21-f6326b4408b6 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:imgn="http://www.immunogen.com/20210922" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityCentralIndexKey" id="Tc_l8EJgyxaFEGfIt78iHOMTw_2_1">0000855654</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:AmendmentFlag" id="Tc_MNnedMjmQEilYzgt5jqE0w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="imgn-20210922.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855654</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-22</xbrli:startDate><xbrli:endDate>2021-09-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_e4a1a085_1f8f_4d26_aadc_76995c1f96c3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;text-align:center;margin:0pt;">UNITED STATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;text-align:center;margin:0pt;">FORM <ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:DocumentType" id="Narr_KHl1lI6xTUmvLyIs5Whxzw">8-K</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_6aYwMmXdnEe5qSa9mT4fgA">September 22, 2021</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;font-weight:bold;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityRegistrantName" id="Narr_9_oL_HAWYUel66ZzCm2Kdg">ImmunoGen, Inc.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_2b3f9c18_ffce_45ab_af8e_c5ead214879e"></a><a id="Tc_sl6GQNm_4E66Iy0wde06ow_2_1"></a><a id="Tc_03ctXOD6UUyGmII7jdfV4A_2_2"></a><a id="Tc_F32UJnlxdkSEair7GW2Lng_2_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;width:100.17%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:38.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_LiCy1kHw3kKoY87UkIgBwg_1_1"><b style="font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityFileNumber" id="Tc_0EOdzQ0uJEOTlX2ttVyfhw_1_2"><b style="font-weight:bold;">0-17999</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityTaxIdentificationNumber" id="Tc_ADPLkNXBF0SwVW5utMwArQ_1_3"><b style="font-weight:bold;">04-2726691</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:27.9pt;"><td style="vertical-align:top;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation)</p></td><td style="vertical-align:top;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(IRS Employer<br />Identification No.)</p></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityAddressAddressLine1" id="Narr_MV7IKZNpnkKtBe9Ideugng"><b style="font-weight:bold;">830 Winter Street</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityAddressCityOrTown" id="Narr_WU-Qagj1dEeAHUDRGlm0TQ"><b style="font-weight:bold;">Waltham, </b></ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityAddressStateOrProvince" id="Narr_GhlpHTF7dEiHzjCFDtmdiw"><b style="font-weight:bold;">MA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:EntityAddressPostalZipCode" id="Narr_pIvjh4USOUOe4b5kwoph-g"><b style="font-weight:bold;">02451</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">(Address of principal executive offices)   (Zip Code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Registrant&#39;s telephone number, including area code: (<ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:CityAreaCode" id="Narr_VxL7KMyjNEyIWwUMO59kaQ">781</ix:nonNumeric>) <ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:LocalPhoneNumber" id="Narr_yKHUqVaB2E-IF-oa3KsXFQ">895-0600</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see </i>General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_RV45WkNiKEGqs639hiUa_g"><span style="font-family:'Segoe UI Symbol';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_1LjY2BvUZkGoKBTV3ntaCg"><span style="font-family:'Segoe UI Symbol';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_yBfs1pa5WESbTLkQkQULew"><span style="font-family:'Segoe UI Symbol';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_wGsGikyR-EacWVQ28EMTwQ"><span style="font-family:'Segoe UI Symbol';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p><a id="_e8d4466d_05d3_45ef_aa67_7e80b3b179f0"></a><a id="Tc__Dk5zZDujECMeN63Co8rqw_1_1"></a><a id="Tc_L1QcABzjo0mal3L7oqyPHw_1_3"></a><a id="Tc_apBwH2fRAEqnB0DFL9THCg_1_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"><tr><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:45.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:Security12bTitle" id="Tc_Rwmq8eR2hU2AcdriIHVsbg_2_1">Common Stock, $.01 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" name="dei:TradingSymbol" id="Tc_X0LFLmLF80-ix-_ZK0tP7w_2_3">IMGN</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_4MUCoMO6NUqJ8m5qBDNJ_w_2_5">Nasdaq Global Select Market</ix:nonNumeric></p></td><td style="vertical-align:top;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_9_22_2021_To_9_22_2021_H38CGEgxb0Ck7zEFGIN7rQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_uKnew_FoKkuhSllVLts_nQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';visibility:hidden;">&#8203;</span></p><p style="display:none;font-size:12pt;line-height:0pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_e4f5f67b_3b29_4733_89db_9b78b742ac13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">On September 22, 2021, the board of directors (the &#8220;Board&#8221;) of ImmunoGen, Inc. (the &#8220;Company&#8221;) elected Dr. Helen Thackray to the Board. The Board increased the size of the Board from seven to eight members and elected Dr. Thackray to fill the resulting vacancy. Dr. Thackray will also serve as a member of the Governance and Nominating Committee of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Dr. Thackray will be compensated for her service as a director in accordance with the Company&#8217;s current non-employee director compensation policy.&#160;As a non-employee director, Dr. Thackray will receive an annual fee of $40,000 for being a member of the Board and an additional annual fee of $7,000 for being a member of the Governance and Nominating Committee. Dr. Thackray will also receive an initial grant of 30,000 deferred stock units (&#8220;DSUs&#8221;) and an initial stock option to purchase 44,000 shares of the Company&#8217;s common stock. In addition, beginning in 2022, Dr. Thackray will be entitled to an annual award of 15,000 DSUs and an annual stock option to purchase 44,000 shares of the Company&#8217;s common stock, prorated in 2022 based on the number of days between the date of Dr. Thackray&#8217;s election and the date of grant of the first annual DSU and stock option award. The foregoing is a summary only and is qualified in its entirety by reference to the Company&#8217;s non-employee director compensation policy, which was filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 17, 2021, and is incorporated herein by reference.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d8aceb78_7e20_418f_ae8e_c2e3c1f3c8f2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ImmunoGen, Inc. </b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Date: September 23, 2021</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">/s/ Renee Lentini____________________ </span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Renee Lentini</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Vice President, Chief Accounting Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "imgn-20210922x8k.htm", "description": "8-K", "secsgml_size_bytes": 32084}]
{"company-data": {"conformed-name": "ImmunoGen, Inc.", "cik": "0000855654", "assigned-sic": "2834", "irs-number": "042726691", "state-of-incorporation": "MA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-17999", "film-number": "211272803"}, "business-address": {"street1": "830 WINTER ST", "city": "WALTHAM", "state": "MA", "zip": "02451", "phone": "(781)895-0600"}, "mail-address": {"street1": "830 WINTER ST", "city": "WALTHAM", "state": "MA", "zip": "02451"}, "former-company": {"former-conformed-name": "IMMUNOGEN INC", "date-changed": "19920703"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
​
Washington, D.C. 20549
​
FORM
8-K
​
CURRENT REPORT
​
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
​
Date of Report (Date of earliest event reported):
September 22, 2021
​
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
​
​
​
​
​
​
​
Massachusetts
0-17999
04-2726691
​
​
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
​
830 Winter Street
,
Waltham,
MA
02451
(Address of principal executive offices)   (Zip Code)
​
Registrant's telephone number, including area code: (
781
)
895-0600
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
​
​
​
​
​
​
​
​
Title of Each Class
Trading Symbol
Name of Each Exchange on Which Registered
​
​
Common Stock, $.01 par value
​
IMGN
​
Nasdaq Global Select Market
​
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
​
Emerging growth company
☐
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 22, 2021, the board of directors (the "Board") of ImmunoGen, Inc. (the "Company") elected Dr. Helen Thackray to the Board. The Board increased the size of the Board from seven to eight members and elected Dr. Thackray to fill the resulting vacancy. Dr. Thackray will also serve as a member of the Governance and Nominating Committee of the Board.
​
Dr. Thackray will be compensated for her service as a director in accordance with the Company's current non-employee director compensation policy. As a non-employee director, Dr. Thackray will receive an annual fee of $40,000 for being a member of the Board and an additional annual fee of $7,000 for being a member of the Governance and Nominating Committee. Dr. Thackray will also receive an initial grant of 30,000 deferred stock units ("DSUs") and an initial stock option to purchase 44,000 shares of the Company's common stock. In addition, beginning in 2022, Dr. Thackray will be entitled to an annual award of 15,000 DSUs and an annual stock option to purchase 44,000 shares of the Company's common stock, prorated in 2022 based on the number of days between the date of Dr. Thackray's election and the date of grant of the first annual DSU and stock option award. The foregoing is a summary only and is qualified in its entirety by reference to the Company's non-employee director compensation policy, which was filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 17, 2021, and is incorporated herein by reference.
​
​
​
SIGNATURE
​
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
​
ImmunoGen, Inc.
​
​
​
Date: September 23, 2021
/s/ Renee Lentini____________________
​
Renee Lentini
​
Vice President, Chief Accounting Officer
​
​
​
​
​